Atlas Trials

Refractory Transformed Non-Hodgkin Lymphoma

9 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Transformed Non-Hodgkin Lymphoma

RecordFirmDate
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643)National Cancer Institute (NCI)2018-09-18
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)Fred Hutchinson Cancer Center2017-12-05
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329)City of Hope Medical Center2017-07-18
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (NCT02628405)Academic and Community Cancer Research United2016-05-20

Track Refractory Transformed Non-Hodgkin Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.